- Home
- WVE
as 12-18-2024 11:44am EST
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
| Founded: | 2012 | Country: | Singapore |
| Employees: | N/A | City: | SINGAPORE |
| Market Cap: | 2.1B | IPO Year: | 2015 |
| Target Price: | $21.60 | AVG Volume (30 days): | 947.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $16.74 | Next Earning Date: | 11-12-2024 |
| Revenue: | $53,610,000 | Revenue Growth: | -37.29% |
| Revenue Growth (this year): | -53.48% | Revenue Growth (next year): | 48.58% |
Stock Insider Trading Activity of Wave Life Sciences Ltd. (WVE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BOLNO PAUL | WVE | President and CEO | Nov 25 '24 | Sell | $15.00 | 50,000 | $750,000.00 | 217,351 | |
| BOLNO PAUL | WVE | President and CEO | Nov 15 '24 | Sell | $14.32 | 51,234 | $733,670.88 | 217,351 | |
| Francis Chris | WVE | See Remarks | Nov 8 '24 | Sell | $16.00 | 36,000 | $576,000.00 | 0 | |
| Francis Chris | WVE | See Remarks | Oct 16 '24 | Sell | $13.56 | 208,836 | $2,855,050.75 | 0 | |
| BOLNO PAUL | WVE | President and CEO | Oct 16 '24 | Sell | $15.00 | 90,474 | $1,357,110.00 | 217,351 | |
| GSK plc | WVE | 10% Owner | Sep 27 '24 | Buy | $8.00 | 2,791,930 | $22,335,440.00 | 16,775,691 | |
| Moran Kyle | WVE | Chief Financial Officer | Sep 25 '24 | Sell | $9.00 | 17,146 | $154,314.00 | 19,777 |
Latest Wave Life Sciences Ltd. News
WVE Breaking Stock News: Dive into WVE Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
22 days ago
Wave Life Sciences to Present at Upcoming Investor Conferences
GlobeNewswire
a month ago
Wave Life Sciences to Present at Jefferies London Healthcare Conference
Simply Wall St.
a month ago
Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20
Simply Wall St.
a month ago
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
a month ago
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
MT Newswires
a month ago
--Truist Securities Adjusts Price Target on Wave Life Sciences to $36 From $17, Keeps Buy Rating
Zacks
a month ago
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
Compare WVE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "WVE Wave Life Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.